International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 022-027
IDA-FLAG CHEMOTHERAPY IN THE REFRACTORY-RELAPSED HEMATOLOGIC MALIGNANCIES
GÜRAY SAYDAM1, ŞAFAK YÜKSEL1, FAHRİ ŞAHİN1, SERDAR BEDİİ OMAY1, FİLİZ BÜYÜKKEÇECİ1
Ege Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalı
Keywords: ida- flag, refractory-relapsed aml, all, nhl
Ida-FLAG chemotherapy, which consists of fludarabine, high dose cytosine arabinoside, idarubucine, and G-CSF, is accepted as an efficient chemotherapeutical regimen in the refractory and/or relapsed AML, ALL, and relapsed malign lymphomas. In this report, the result of the patients who have received Ida-FLAG regimen in our center , have been evaluated retrospectively. Total 10 patients were included and mean age was 41.1±11,2 years. Seven of them were relapsed or refractory AML, 2 of them relapsed ALL and one patient was transformed low grade lymphoma. All of the patients had received multiple chemotherapy regimens before. All patients died because of febrile neturopenia, hemorrhage and bone marrow failure. In the literature, Ida-FLAG results are better and the mortality is less. In our patients, the mortality was high, most probably because of very bad prognosis patient selection. With our results. It can be suggested that, Ida-FLAG is not a good choice in the selected patient group of relapsed-refractory, multiple chemotherapy administered patients.
GÜRAY SAYDAM1, ŞAFAK YÜKSEL1, FAHRİ ŞAHİN1, SERDAR BEDİİ OMAY1, FİLİZ BÜYÜKKEÇECİ1
Ege Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalı
Keywords: ida- flag, refractory-relapsed aml, all, nhl
Ida-FLAG chemotherapy, which consists of fludarabine, high dose cytosine arabinoside, idarubucine, and G-CSF, is accepted as an efficient chemotherapeutical regimen in the refractory and/or relapsed AML, ALL, and relapsed malign lymphomas. In this report, the result of the patients who have received Ida-FLAG regimen in our center , have been evaluated retrospectively. Total 10 patients were included and mean age was 41.1±11,2 years. Seven of them were relapsed or refractory AML, 2 of them relapsed ALL and one patient was transformed low grade lymphoma. All of the patients had received multiple chemotherapy regimens before. All patients died because of febrile neturopenia, hemorrhage and bone marrow failure. In the literature, Ida-FLAG results are better and the mortality is less. In our patients, the mortality was high, most probably because of very bad prognosis patient selection. With our results. It can be suggested that, Ida-FLAG is not a good choice in the selected patient group of relapsed-refractory, multiple chemotherapy administered patients.